A bipartisan group of US lawmakers has called on the Department of Health and Human Services (HHS) to enforce compliance with the 340B drug discount program, citing a dispute in which Eli Lilly has restricted hospital access to discounted medications. The 340B programme, established under federal law, requires participating manufacturers to provide substantial price reductions on outpatient drugs to eligible healthcare institutions, including safety-net hospitals and cancer centres.
Key takeaways
- Lawmakers have formally requested HHS intervention in a dispute between Eli Lilly and hospitals over 340B drug discount access
- The 340B program requires pharmaceutical manufacturers to offer discounted prices to eligible healthcare facilities including public and non-profit hospitals
- Restrictions on drug discounts can increase costs for hospitals serving vulnerable populations and limit patient access to medicines
- HHS has regulatory authority to enforce manufacturer compliance with 340B programme requirements
The 340B Programme and its Purpose
The 340B drug discount program is a federal initiative established to help safety-net hospitals, public health agencies, and other eligible healthcare institutions reduce medication acquisition costs. According to HHS, the program requires manufacturers to extend significant discounts on outpatient drugs to qualifying providers, allowing these institutions to reinvest savings into patient care and services for vulnerable populations.
Eligible 340B participants typically include disproportionate share hospitals (DSH), federally qualified health centres, state and local health agencies, and certain non-profit hospitals serving low-income communities. The programme is designed to stretch limited healthcare budgets, particularly for institutions treating uninsured and underinsured patients.
340B Program Impact on Hospital Drug Acquisition Costs
Estimated cost reductions for eligible healthcare institutions through manufacturer discount participation
Source: Illustrative estimates based on 340B programme structure | Georgian Medical Journal News
The Eli Lilly Dispute and Legislative Response
According to reports covered by STAT News, Eli Lilly has imposed restrictions limiting certain hospitals’ access to its drugs under the 340B program. In response, lawmakers sent a formal letter to HHS requesting regulatory enforcement, arguing that such restrictions contravene the program’s statutory purpose and harm vulnerable patient populations. The dispute centres on whether manufacturers can unilaterally restrict 340B programme participation or eligibility.
The legislative action signals growing concern among members of Congress about pharmaceutical manufacturer practices that may undermine safety-net healthcare delivery. A Centers for Medicare and Medicaid Services (CMS) representative has not yet publicly commented on whether enforcement action is planned, though HHS maintains administrative authority over 340B compliance.
Lawmakers are pressing HHS to enforce the 340B drug discount program, arguing that manufacturer restrictions on hospital access undermine the program’s purpose of supporting safety-net healthcare institutions and vulnerable patient populations.
— Bipartisan Congressional delegation, letter to HHS (July 2026)
Implications for Hospital Operations and Patient Access
When manufacturers restrict 340B access, hospital drug acquisition costs rise significantly. This affects budgets for clinical services, particularly in safety-net hospitals where margins are already thin. Higher drug costs can delay treatment initiation, reduce medication availability, or force institutions to prioritize treatments—ultimately affecting patient outcomes in vulnerable populations.
The dispute also raises broader questions about manufacturer authority in federal drug pricing programmes. If manufacturers can unilaterally restrict 340B access without HHS intervention, the program’s statutory protections may erode, affecting hundreds of eligible institutions across the United States.
What this means
Frequently asked questions
What is the 340B drug discount program?
The 340B program is a federal initiative requiring pharmaceutical manufacturers to provide substantial discounts on outpatient drugs to eligible healthcare institutions—including safety-net hospitals, public health agencies, and federally qualified health centres. The program was designed to help these institutions stretch limited budgets and reinvest savings into patient care services.
Can pharmaceutical manufacturers refuse to participate in 340B?
Manufacturers cannot refuse to participate in 340B for covered drugs; participation is mandated by federal law. However, disputes have arisen regarding restrictions manufacturers impose on which hospitals can access discounts, and whether such restrictions comply with statutory requirements. The current dispute with Eli Lilly centres on these restriction practices.
What authority does HHS have to enforce 340B compliance?
The HHS Administration for Strategic Preparedness and Response (ASPR) and CMS oversee 340B program administration and have regulatory authority to investigate manufacturer violations and enforce compliance. Congressional pressure aims to activate this enforcement authority in the Eli Lilly dispute.
The outcome of this dispute may set precedent for how HHS interprets manufacturer obligations under the 340B program and whether similar restrictions from other pharmaceutical companies will trigger regulatory action. As safety-net hospitals increasingly depend on 340B savings to sustain operations, clarification of manufacturer compliance requirements remains a priority for both Congress and health policy advocates.
Source: STAT News — Lawmakers urge Eli Lilly to provide 340B drug discounts to hospitals
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
